Regenerative medicine company Novadip Biosciences revealed on Tuesday the election of Jeff Abbey as its chief executive officer.
Effective early 2019, Abbey will succeed the outgoing Jean-Francois Pollet.
Since 2002, Abbey has worked with Argos Therapeutics Inc, an immuno-oncology cell therapy company, in multiple positions including president and chief executive officer for the past eight years.
The company's lead programme is an autologous three-dimensional cell therapy that has completed enrolment of a phase I/IIa trial in spinal fusion patients. Its second clinical programme is currently enrolling patients with non-healing bone fractures.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma